These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2857024)

  • 1. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus.
    Assan R; Feutren G; Debray-Sachs M; Quiniou-Debrie MC; Laborie C; Thomas G; Chatenoud L; Bach JF
    Lancet; 1985 Jan; 1(8420):67-71. PubMed ID: 2857024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin.
    Bougnères PF; Landais P; Boisson C; Carel JC; Frament N; Boitard C; Chaussain JL; Bach JF
    Diabetes; 1990 Oct; 39(10):1264-72. PubMed ID: 2210078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disappearance and reappearance of islet cell cytoplasmic antibodies in cyclosporin-treated insulin-dependent diabetics.
    Mandrup-Poulsen T; Nerup J; Stiller CR; Marner B; Bille G; Heinrichs D; Martell R; Dupre J; Keown PA; Jenner MR
    Lancet; 1985 Mar; 1(8429):599-602. PubMed ID: 2857945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin.
    Assan R; Feutren G; Sirmai J; Laborie C; Boitard C; Vexiau P; Du Rostu H; Rodier M; Figoni M; Vague P
    Diabetes; 1990 Jul; 39(7):768-74. PubMed ID: 2191883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of predictive value of islet cell antibodies, insulin antibodies, and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients. The Canadian-European Randomized Control Trial Group.
    Mandrup-Poulsen T; Mølvig J; Andersen HU; Helqvist S; Spinas GA; Munck M
    Diabetes; 1990 Feb; 39(2):204-10. PubMed ID: 2227128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin requirements and residual beta-cell function 12 months after concluding immunotherapy in type I diabetic patients treated with combined azathioprine and thymostimulin administration for one year.
    Moncada E; Subirá ML; Oleaga A; Goñi F; Sánchez-Ibarrola A; Monreal M; Sevilla M; Goñi MJ; Yoldi A; Terán D
    J Autoimmun; 1990 Oct; 3(5):625-38. PubMed ID: 2252531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased reduction in fasting C-peptide is associated with islet cell antibodies in type 1 (insulin-dependent) diabetic patients.
    Marner B; Agner T; Binder C; Lernmark A; Nerup J; Mandrup-Poulsen T; Walldorff S
    Diabetologia; 1985 Dec; 28(12):875-80. PubMed ID: 3912242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of insulin release in vitro mediated by mononuclear cells from diabetic patients treated with cyclosporin A or placebo.
    Debray-Sachs M; Sai P; Feutren G; Lang F; Maugendre D; Boitard C; Hors J; Bach JF
    Diabetes; 1988 Jul; 37(7):873-7. PubMed ID: 3290005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cyclosporin A treatment on the production of antibody in insulin-dependent (type I) diabetic patients.
    Boitard C; Feutren G; Castano L; Debray-Sachs M; Assan R; Hors J; Bach JF
    J Clin Invest; 1987 Dec; 80(6):1607-12. PubMed ID: 3316278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypersensitivity to insulin during remissions in cyclosporin-treated IDDM patients.
    Burcelin RG; Eddouks M; Beylot M; Normand S; Boitard C; Feutren G; Landais P; Riou JP; Girard JR; Bach JF
    Diabetes Care; 1993 Jun; 16(6):881-8. PubMed ID: 8325202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group.
    Diabetes; 1988 Nov; 37(11):1574-82. PubMed ID: 2903105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment. The Canadian-European Randomized Control Trial Group.
    Petersen JS; Dyrberg T; Karlsen AE; Mølvig J; Michelsen B; Nerup J; Mandrup-Poulsen T
    Diabetes; 1994 Nov; 43(11):1291-6. PubMed ID: 7926302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural course of remission in IDDM during 1st yr after diagnosis.
    Martin S; Pawlowski B; Greulich B; Ziegler AG; Mandrup-Poulsen T; Mahon J
    Diabetes Care; 1992 Jan; 15(1):66-74. PubMed ID: 1737543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a short prednisone regime at clinical onset of type 1 diabetes.
    Goday A; Pujol-Borrell R; Fernandez J; Casamitjana R; Rios M; Vilardell E; Gomis R
    Diabetes Res Clin Pract; 1993 Apr; 20(1):39-46. PubMed ID: 8344127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.
    Stiller CR; Dupré J; Gent M; Jenner MR; Keown PA; Laupacis A; Martell R; Rodger NW; von Graffenried B; Wolfe BM
    Science; 1984 Mar; 223(4643):1362-7. PubMed ID: 6367043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes.
    Vidal J; Fernández-Balsells M; Sesmilo G; Aguilera E; Casamitjana R; Gomis R; Conget I
    Diabetes Care; 2000 Mar; 23(3):360-4. PubMed ID: 10868866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proinsulin and C-peptide at onset and during 12 months cyclosporin treatment of type 1 (insulin-dependent) diabetes mellitus.
    Snorgaard O; Hartling SG; Binder C
    Diabetologia; 1990 Jan; 33(1):36-42. PubMed ID: 2303172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.
    Feutren G; Papoz L; Assan R; Vialettes B; Karsenty G; Vexiau P; Du Rostu H; Rodier M; Sirmai J; Lallemand A
    Lancet; 1986 Jul; 2(8499):119-24. PubMed ID: 2873396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
    Keymeulen B; Vandemeulebroucke E; Ziegler AG; Mathieu C; Kaufman L; Hale G; Gorus F; Goldman M; Walter M; Candon S; Schandene L; Crenier L; De Block C; Seigneurin JM; De Pauw P; Pierard D; Weets I; Rebello P; Bird P; Berrie E; Frewin M; Waldmann H; Bach JF; Pipeleers D; Chatenoud L
    N Engl J Med; 2005 Jun; 352(25):2598-608. PubMed ID: 15972866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporin A suppresses insulin autoantibodies and heterologous insulin antibodies in type I diabetic children.
    Castaño L; Boîtard C; Bougnères PF
    Diabetes; 1988 Aug; 37(8):1049-52. PubMed ID: 3292324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.